Which beta-blocker is most effective in heart failure?

Cardiovascular Drugs and Therapy

Volumn 24, Issue 4, 2010, Pages 351-358

  Remme, Willem J ^a  

^a Sticares Cardiovascular Research Foundation   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NEBIVOLOL; PLACEBO; PROPRANOLOL;

ACUTE HEART INFARCTION; ANTIOXIDANT ACTIVITY; APOPTOSIS; BETA ADRENERGIC RECEPTOR BLOCKING; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; MORTALITY; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROGNOSIS; SYMPATHETIC BLOCKING; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 78149359059     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-010-6247-7     Document Type: Conference Paper

References (66)

1. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-55. (Pubitemid 26152713)
2. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomised trial. Lancet. 1999;353:9-13.
3. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-7.
4. Packer M, Coats AJS, Fowler MB, et al. For the Carvedilol Prospective Randomized Cumulative Survival Study Group (COPERNICUS). Effect of carvedilol on survival in severe chronic heart failure. New Engl J Med. 2001;344:1651-8. (Pubitemid 32479962)
5. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:1385-90.
6. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215-25.
7. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation. 2005;112: e154-235.
8. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J. 2005;26:1115-40. (Pubitemid 40839912)
9. Cohn JN. Remodeling as an end-point in heart failure therapy. Cardiovasc Drugs Ther. 2004;18:7-8.
10. Remme WJ. Pharmacological modulation of cardiovascular remodelling: a guide to heart failure therapy. Cardiovasc Drugs Ther. 2003;17:349-60.
11. Yamazaki T, Komuro I, Kudoh S, et al. Role of ion channels and exchangers in mechanical stretch-induced cardiomyocyte hypertrophy. Circ Res. 1998;82:430-7.
12. Ungureanu-Longrois D, Balligand JL, Simmons SW, et al. Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to β-adrenergic agonists. Circ Res. 1995;77:494-502.
13. Li X, Moody MR, Engl D, et al. Cardiac-specific overexpression of tumor necrosis factor-α causes oxidative stress and contractile dysfunction in mouse diaphragm. Circulation. 2000;102:1690-6.
14. Francis GS, Benedict C, Johnston DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-9.
15. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;24:549-64.
16. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of beta-adrenergic pathway. Circulation. 1998;98:1329-34.
17. Tan LB, Benjamin IJ, Clark WA. Beta-adrenergic receptor desensitization may serve a cardioprotective role. Cardiovasc Res. 1992;26:608-14.
18. Prabhu SD, Wang G, Luo J, et al. Beta-adrenergic receptor blockade modulates Bcl-X (S) expression and reduces apoptosis in failing myocardium. J Mol Cell Cardiol. 2003;35:483-93.
19. 2-adrenergic overexpression exacerbates development of heart failure after aortic stenosis. Circulation. 2000;101:71-7.
20. 2-adrenergic stimulation in animals susceptible to sudden death. Circulation. 1997;96:1914-22.
21. Molenaar P, Christ T, Ravens U, Kaumann A. Carvedilol blocks beta 2-more than beta-1 adrenoceptors in the heart. Cardiovasc Res. 2006;69:128-39.
22. Kindermann M, Maack C, Schaller S, et al. Carvedilol but not metoprolol reduces β-adrenergic responsiveness after complete elimination from plasma in vivo. Circulation. 2004;109:3182-9.
23. 3-adrenoceptor expression in chronic heart failure. Cardiovasc Drugs Ther. 2007;21:85-90.
24. Wisler JW, De Wire SM, Whalen EJ, et al. A unique mechanism of β-blocker action: carvedilol stimulates β-arrestin signaling. Proc Natl Acad Sci. 2007;104:16657-62.
25. Nicolaides LA, Poornima I, Parikh P, Magovern M, Shen YT, Shannon RP. The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy. J Am Coll Cardiol. 2006;47:1871-81.
26. Hanada K, Asari K, Saito M, Kawana J, Mita M, Ogata H. Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of enantiomeres. Eur J Pharmacol. 2008;589:194-200.
27. Lai K-B, Sanderson JE, Yu C-M. Suppression of collagen production in norepinephrine stimulated cardiac fibroblasts culture: differential effect of α and β-adrenoceptor antagonism. Cardiovasc Drugs Ther. 2009;23:271-80.
28. Batenburg WW, van Esch JH, Garrelds IM, et al. Carvedilolinduced antagonism of angiotensin II: a matter of alpha-1 adrenoceptor blockade. J Hypertens. 2006;24:1355-63.
29. Bartholomeu JB, Vanzelli AS, Rolim NP, et al. Intracellular mechanisms of specific beta-adrenoceptor antagonists involved in improved cardiac function and survival in a genetic model of heart failure. J Mol Cell Cardiol. 2008;45:240-9.
30. Wang R, Miura T, Hanada N, et al. Pleiotropic effects of the betaadrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther. 2006;318:45-52.
31. Kametani R, Miura T, Harada N, et al. Carvedilol inhibits mitochondrial oxygen consumption and superoxide production during calcium overload in isolated heart mitochondria. Circ J. 2006;70:321-6.
32. Brixius K, Lu R, Boelck B, et al. Chronic treatment with carvedilol improves Ca (2+)-dependent ATP consumption in triton X-skinned fiber preparations of human myocardium. J Pharmacol Exp Ther. 2007;322:222-7.
33. Sun YL, Hu SJ, Wang LH, et al. Effect of beta-blockers on cardiac function and calcium handling protein in postinfarction heart failure rats. Chest. 2005;128:1812-21.
34. Kohno T, Yoshikawa T, Yoshizawa A, et al. Carvedilol exerts more potent antiadrenergics effect than metoprolol in heart failure. Cardiovasc Drugs Ther. 2005;19:347-55.
35. Azevedo ER, Kubo T, Mak S, et al. Non-selective versus selective β-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation. 2001;104:2194-9.
36. Sanderson JE, Chan SKW, Yip G, et al. Beta-blockade in heart failure. A comparison of carvedilol with metoprolol. J Am Coll Cardiol. 1999;34:1522-8.
37. Metra M, Gibbini R, Nodari S, Boldi E, Modena MG, Dei Cas L. Differential effects of beta-blockers in patients with heart failure. A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation. 2000;102:546-51.
38. Kukin ML, Kalman J, Charney Rh, et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation. 1999;99:2645-51.
39. Packer M, Antonopoulos GV, Berlin JA, Chittams J, Konstam MA, Udelson JE. Comparative effects of carvedilol and metoprolol on left ventricular ejection fraction in heart failure: results of a meta-analysis. Am Heart J. 2001;141:899-907.
40. Poole-Wilson PA, Swedberg K, Cleland JGF, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure. Results of the Carvedilol Or Metoprolol European Trial (COMET). Lancet. 2003;362:7-13.
41. Metra M, Torp-Pedersen C, Swedberg K, et al. Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results of the COMET trial. Eur Heart J. 2005;26:2259-68.
42. Kukin ML, Mannino MM, Freudenberger RS, Kalman J, Buchholz-Varley C, Ocampo O. Hemodynamic comparison of twice daily metoprolol tartrate with once daily metoprolol succinate in congestive heart failure. J Am Coll Cardiol. 2000;35:45-50.
43. Wikstrand J, Hjalmarson A, Waagstein F, et al. MERIT-HF Study Group. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: Analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF). J Am Coll Cardiol. 2002;40:491-8. (Pubitemid 34833165)
44. Herlitz J, Dellborg M, Karlson BW, et al. Similar risk reduction of death of extended-release metoprolol once daily and immediaterelease metoprolol twice daily during 5 years after myocardial infarction. Cardiovasc Drugs Ther. 1999;13:127-35.
45. Remme WJ, Torp-Pedersen C, Cleland JGF, et al. Carvedilol protects better against vascular events than metoprolol in heart failure. Results from COMET. J Am Coll Cardiol. 2007;49:963-71.
46. Von zur Muhlen B, Millgard J, Lind L. Divergent effects of different beta-blocking agents on endothelin-dependent vasodilatation in the human forearm. Blood Press. 2000;9:287-92.
47. Intengan HD, Schiffrin EL. Disparate effects of carvedilol versus metoprolol treatment of stroke-prone spontaneously hypertensive rats on endothelial function of resistance arteries. J Cardiovasc Pharmacol. 2000;35:763-8.
48. Matsuda Y, Akita H, Terashima M, Shiga N, Kanazawa K, Yokoyama M. Carvedilol improves endothelium-dependent dilatation in patients with coronary artery disease. Am Heart J. 2000;140:753-9.
49. Lopez BL, Christopher TA, Yue TL, Ruffolo R, Feuerstein GZ, Ma XL. Carvedilol, a new beta-adrenoceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. Pharmacology. 1995;51:165-73.
50. Gao F, Chen J, Lopez BL, et al. Comparison of bisoprolol and carvedilol cardioprotection in a rabbit ischemia and reperfusion model. Eur J Pharmacol. 2000;406:109-16.
51. Ma XL, Yue TL, Lopez BL, et al. Carvedilol, a new betaadrenoceptor blocker and free radical scavenger attenuates myocardial ischemia reperfusion injury in hypercholesterolemic rabbits. J Pharmacol Exp Ther. 1996;277:128-36.
52. Oliveira PJ, Rolo AP, Monteiro P, Goncalves L, Palmeira CM, Moreno AJ. Impact of carvedilol on the mitochondrial damage induced by hypxanthine and xantine oxidase-what role in myocardial ischemia and reperfusion? Rev Port Cardiol. 2002;21:1447-55.
53. Asanuma H, Minamino T, Sanada S, et al. Beta-adrenoceptor blocker carvedilol provides cardioprotection via an adenosine-dependent mechanism in ischemic canine hearts. Circulation. 2004;109:2773-9.
54. Romeo F, Li D, Shi M, Mehta JL. Carvedilol prevents epinephrine-induced apoptosis in human coronary artery endothelial cells: modulation of Fas/Fas ligand and caspase-3 pathway. Cardiovasc Res. 2000;45:788-94.
55. Rossig L, Haendeler J, Mallat Z, et al. Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. J Am Coll Cardiol. 2000;36:2081-9.
56. Chen JW, Lin FY, Chen YH, Wu T, Chen YL, Lin SJ. Carvedilol inhibits tumor necrosis factor-alpha-induced endothelial transcription factor activation, adhesion molecule expression and adhesiveness to human mononuclear cells. Arterioscler Thromb Vasc Biol. 2004;24:2075-81.
57. Kurz T, Richardt D, Gorge B, et al. Differential effects of carvedilol on norepinephrine release in normoxic and ischemic heart. J Cardiovasc Pharmacol. 2000;36:96-100.
58. Torp-Pedersen C, Metra M, Charlesworth A, et al. Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET). Heart. 2007;93:968-73.
59. Fonseca V, Bakris GL, Bell DSH, et al. Differential effect of betablocker therapy on insulin resistance as a function of insulin sensitizer use: results of GEMINI. Diabet Med. 2007;24:759-63.
60. Basat O, Ucak S, Seber S, Oztekin E, Altuntas Y. After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol. 2006;95:99-104.
61. Bell DSH, Bakris GL, McGill JB. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. Diab Obes Metab. 2009;11:234-8.
62. Messerli FH, Bell DSH, Fonseca V, et al. Body weight changes with beta-blocker use: results of GEMINI. Am J Med. 2007;120:10-5.
63. Agostoni P, Contini M, Cattadori G, et al. Lung function with carvedilol and bisoprolol in chronic heart failure: Is β selectivity relevant? Eur J Heart Fail. 2007;9:827-33.
64. Guazzi M, Agostoni P, Maturri M, Pontone G, Guazzi MD. Pulmonary function, cardiac function and exercise capacity in a follow-up of patients with congestive heart failure treated with carvedilol. Am Heart J. 1999;138:460-7.
65. Kotlyar E, Keogh AM, Macdonald PS, Arnold RH, McCaffrey DJ, Glanville AR. Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. J Heart Lung Transplant. 2002;21:1290-5.
66. Agostoni P, Palermo P, Contini M. Respiratory effects of β-blocker therapy in heart failure. Cardiovasc Drugs Ther. 2009;23:377-84.